Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds

Rhea-AI Summary

Revelation Biosciences Inc. (NASDAQ: REVB) has announced a definitive agreement for the immediate exercise of certain outstanding warrants. The exercise will result in $3.8 million in gross proceeds for the company. Key details include:

- Exercise of warrants to purchase up to 2,548,060 shares of common stock
- Reduced exercise price of $1.50 per share
- Issuance of new warrants in a private placement
- New warrants for up to 5,096,120 shares at $1.00 per share
- Five-year term for new warrants
- Roth Capital Partners acting as financial advisor

The company plans to file a resale registration statement within 20 days of closing to register the resale of shares underlying the new warrants.

Positive

• Immediate influx of $3.8 million in gross proceeds from warrant exercise
• Issuance of new warrants at a lower price ($1.00) than the current exercise ($1.50), potentially attracting more investment
• New warrants have a five-year term, providing long-term potential for additional capital

Negative

• Potential dilution of existing shareholders due to the issuance of new shares and warrants
• The reduced exercise price of $1.50 for existing warrants may indicate a lower valuation than previously anticipated

Financial Analyst

Revelation Biosciences' warrant exercise deal is a double-edged sword. On one hand, it provides an immediate $3.8 million cash infusion, bolstering the company's liquidity. This could fund ongoing R&D efforts in trained immunity. However, the dilutive effect is significant, with 2,548,060 new shares being issued at a 25% discount to the previous warrant price. The new warrants, if exercised, would lead to further dilution. While this move improves short-term cash position, it may put downward pressure on the stock price due to increased share count and potential future dilution. Investors should closely monitor how Revelation utilizes this capital to drive value creation.

Biotech Research Analyst

This financial maneuver, while providing immediate capital, raises questions about Revelation's pipeline progress and cash burn rate. The company's focus on trained immunity for disease prevention and treatment is promising, but the need for this financing suggests potential challenges in advancing their programs. The reduced warrant exercise price of $1.50 per share, down from the original price, indicates pressure to secure funding. Investors should seek clarity on the specific allocation of these funds and upcoming milestones in Revelation's development programs to better assess the company's prospects and the potential impact of this dilution on long-term value creation.

SAN DIEGO--(BUSINESS WIRE)-- Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on harnessing the power of trained immunity for the prevention and treatment of disease, announced today the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 2,548,060 shares of common stock, issued by the Company on February 5, 2024 (the “Existing Warrants”), at the reduced exercise price of $1.50 per share. The shares of common stock issuable upon exercise of the Existing Warrants are registered pursuant to an effective registration statement on Form S-1 (File No. 333-276232). The closing of the offering is expected to occur on or about August 22, 2024, subject to satisfaction of customary closing conditions.

Roth Capital Partners is acting as the Company’s financial advisor for this transaction.

In consideration for the immediate exercise of the warrants for cash, the exercising holders will receive new warrants to purchase shares of common stock in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "1933 Act"). The new warrants will be exercisable into an aggregate of up to 5,096,120 shares of common stock, at an exercise price of $1.00 per share (priced at-the-market under the rules of the Nasdaq Stock Market) and have a term of exercise equal to five years. The securities offered in the private placement have not been registered under the Securities Act of 1933, as amended, or applicable under state securities laws. Accordingly, the securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. As part of the transaction, the Company has agreed to file a resale registration statement on Form S-3 with the Securities and Exchange Commission within 20 days of the closing to register the resale of the shares of common stock underlying the new warrants issued in the private placement.

This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on harnessing the power of trained immunity for the prevention and treatment of disease using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as a prevention for acute kidney injury, and for the treatment of chronic kidney disease.

For more information on Revelation, please visit www.RevBiosciences.com.

Forward-Looking Statement

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words "anticipate", "believe", "expect", "estimate", "plan", "outlook", and "project" and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240821710145/en/

Sandra Vedrick

Vice President, Investor Relations & Human Resources

Revelation Biosciences Inc.

Email: svedrick@revbiosciences.com

and

Chester Zygmont, III

Chief Financial Officer

Revelation Biosciences Inc.

Email: czygmont@revbiosciences.com

Source: Revelation Biosciences Inc.

FAQ

What is the total amount of gross proceeds Revelation Biosciences (REVB) expects from the warrant exercise?

Revelation Biosciences (REVB) expects to receive $3.8 million in gross proceeds from the immediate exercise of certain outstanding warrants.

How many new warrants will Revelation Biosciences (REVB) issue in the private placement?

Revelation Biosciences (REVB) will issue new warrants for up to 5,096,120 shares of common stock in the private placement.

What is the exercise price and term for the new warrants issued by Revelation Biosciences (REVB)?

The new warrants issued by Revelation Biosciences (REVB) have an exercise price of $1.00 per share and a term of exercise equal to five years.

When is the expected closing date for Revelation Biosciences' (REVB) warrant exercise agreement?

The closing of the offering is expected to occur on or about August 22, 2024, subject to satisfaction of customary closing conditions.